Our integrated platform is applied end to end across our own programs: target identification, functional binder screening, and computational prediction of on-target and off-target liabilities, coupled with wet lab assessment.
With this, we are working on a pipeline of first-in-class or best-in-class TCEs against various solid tumor indications.
Program
Modality
Discovery
Preclinical
Clinical
Small Cell Lung Cancer
Ovarian Cancer
Hepatocellular Carcinoma
Partner with Us
We work with biopharma, protein engineering and AI teams in two ways.
Asset partnerships
We partner our multispecific TCE programs with biopharma companies to bring new options to solid tumor patients faster. Depending on the program and stage, partnerships can include:
- Exclusive licenses to individual programs, either worldwide or by region
- Co-development, sharing development costs and the option to co-commercialize
- Option agreements, where a partner supports a program through a defined milestone and holds an option to license it
Platform partnerships
We partner our TCELERATORTM platform with biopharma, protein engineering and AI teams to screen binders by function and generate functional data at scale. Depending on your goals, partnerships can include:
- Pilot screen: Bring your binders or library. We screen them functionally and return ranked hits, and you keep all rights to your molecules and data.
- Discovery collaboration: You nominate targets, we discover TCEs against them on TCELERATOR, and you hold an option to license the resulting candidates.
- Data partnership: Design-test loops with AI labs that generate functional labels for model training.
Interested in partnering with us? Please contact us.
